New drug targets AKT mutation in Hard-to-Treat cancers
NCT ID NCT04439123
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests capivasertib (AZD5363) in 35 patients with advanced cancers that have an AKT mutation. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Capivasertib (also called AZD5363), a drug that blocks a protein called AKT which helps cancer cells grow.
- What this could lead to
- If it works, this could point toward a treatment for cancers with AKT mutations, especially when other options have failed.
- What could go wrong
- This is a small, early-phase trial (35 participants) with no control group, so results may not apply broadly. The drug may not shrink tumors or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?